摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-acetamido-4-(4-phenylpiperazin-yl)-6-(1,2,3-trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid | 1392415-50-7

中文名称
——
中文别名
——
英文名称
5-acetamido-4-(4-phenylpiperazin-yl)-6-(1,2,3-trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid
英文别名
(2R,3R,4S)-3-acetamido-4-(4-phenylpiperazin-1-yl)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
5-acetamido-4-(4-phenylpiperazin-yl)-6-(1,2,3-trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid化学式
CAS
1392415-50-7
化学式
C21H29N3O7
mdl
——
分子量
435.477
InChiKey
VBQIZUPBSPTEJS-APQLOABGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -2.5
  • 重原子数:
    31
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    143
  • 氢给体数:
    5
  • 氢受体数:
    9

反应信息

  • 作为产物:
    描述:
    (1S,2R)-1-((2R,3R,4S,6R)-3-acetamido-4,6-diacetoxy-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)propane-1,2,3-triyl triacetate 在 吡啶4-二甲氨基吡啶三氟甲磺酸三甲基硅酯 、 sodium hydroxide 作用下, 以 甲醇乙腈 为溶剂, 生成 5-acetamido-4-(4-phenylpiperazin-yl)-6-(1,2,3-trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid
    参考文献:
    名称:
    Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities
    摘要:
    With the introduction of bioisosteres of the guanidinium group together with scaffold hopping, 35 zanamivir analogs with C-4-modification were synthesized, and their inhibitory activities against both group-1 and group-2 neuraminidase (H5N1 and H3N2) were determined. Compound 026 exerts the most potency, with IC50 values of 0.58 and 2.72 mu M against N2 and N1, respectively. Further preliminary anti-avian influenza virus (AIV, H5N1) activities against infected MDCK cells were evaluated, and D5 exerts similar to 58% protective against AIV infection, which was comparable to zanamivir (similar to 67%). In a rat pharmacokinetic study, compound D5 showed an increased plasma half-life (t(1/2)) compared to zanamivir following either intravenous or oral administration. This study may represent a new start point for the future development of improved anti-AIV agents. (C) 2012 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2012.06.033
点击查看最新优质反应信息

文献信息

  • Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities
    作者:Deju Ye、Woo-Jin Shin、Ning Li、Wei Tang、Enguang Feng、Jian Li、Pei-Lan He、Jian-Ping Zuo、Hanjo Kim、Ky-Youb Nam、Weiliang Zhu、Baik-Lin Seong、Kyoung Tai No、Hualiang Jiang、Hong Liu
    DOI:10.1016/j.ejmech.2012.06.033
    日期:2012.8
    With the introduction of bioisosteres of the guanidinium group together with scaffold hopping, 35 zanamivir analogs with C-4-modification were synthesized, and their inhibitory activities against both group-1 and group-2 neuraminidase (H5N1 and H3N2) were determined. Compound 026 exerts the most potency, with IC50 values of 0.58 and 2.72 mu M against N2 and N1, respectively. Further preliminary anti-avian influenza virus (AIV, H5N1) activities against infected MDCK cells were evaluated, and D5 exerts similar to 58% protective against AIV infection, which was comparable to zanamivir (similar to 67%). In a rat pharmacokinetic study, compound D5 showed an increased plasma half-life (t(1/2)) compared to zanamivir following either intravenous or oral administration. This study may represent a new start point for the future development of improved anti-AIV agents. (C) 2012 Elsevier Masson SAS. All rights reserved.
查看更多